Version 1
: Received: 19 June 2024 / Approved: 19 June 2024 / Online: 19 June 2024 (11:55:41 CEST)
How to cite:
MARTINEZ, R. O.; CELAYA, J. A. D. L. P.; MUÑIZ, N. R.; ISLAS, P. B.; RANGEL, X. C.; IBARRA, M. A. Daratumumab Post Maintenance after Relapse in Multiple Myeloma. Preprints2024, 2024061349. https://doi.org/10.20944/preprints202406.1349.v1
MARTINEZ, R. O.; CELAYA, J. A. D. L. P.; MUÑIZ, N. R.; ISLAS, P. B.; RANGEL, X. C.; IBARRA, M. A. Daratumumab Post Maintenance after Relapse in Multiple Myeloma. Preprints 2024, 2024061349. https://doi.org/10.20944/preprints202406.1349.v1
MARTINEZ, R. O.; CELAYA, J. A. D. L. P.; MUÑIZ, N. R.; ISLAS, P. B.; RANGEL, X. C.; IBARRA, M. A. Daratumumab Post Maintenance after Relapse in Multiple Myeloma. Preprints2024, 2024061349. https://doi.org/10.20944/preprints202406.1349.v1
APA Style
MARTINEZ, R. O., CELAYA, J. A. D. L. P., MUÑIZ, N. R., ISLAS, P. B., RANGEL, X. C., & IBARRA, M. A. (2024). Daratumumab Post Maintenance after Relapse in Multiple Myeloma. Preprints. https://doi.org/10.20944/preprints202406.1349.v1
Chicago/Turabian Style
MARTINEZ, R. O., XOCHITL COTA RANGEL and MARTHA ALVARADO IBARRA. 2024 "Daratumumab Post Maintenance after Relapse in Multiple Myeloma" Preprints. https://doi.org/10.20944/preprints202406.1349.v1
Abstract
We present 4 cases of patients diagnosed with multiple myeloma initially treated without monoclonal antibodies. It was decided to provide the benefit of the drug after maintenance with lenalidomide was initiated to consolidate the post-maintenance response followed by monitoring without any kind of treatment.
In this series of 4 cases 100% of the patients achieved a strict complete response with undetectable Minimal Residual Disease (MRD) for flow cytometry after post-maintenance consolidation with daratumumab regardless of the scheme used as induction/consolidation, as well as whether they had received HSCT. Until the last follow-up the patients are under surveillance with no evidence of progression. It should be noted that 3 of 4 of these patients debuted with high-risk disease.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.